Abstract: The present invention aims to provide a novel gene having a reverse transcriptase motif. The invention isolates a novel gene having a reverse transcriptase motif, and gives its complete base sequence determined. The invention also provides a protein encoded by the gene, and an antibody against the protein. The use of them is useful in developing a method for detecting telomerase activity, a method for detecting a cancer cell, a telomerase activity inhibitor, and a method for screening a telomerase activity inhibitor.

Abstract: An iron based alloy material for a thixocasting process and a method for casting the material which extends the service life of dies by inhibiting solidification contraction, and in which casting defects such as size variations and cracks can be inhibited. The material comprises 1.6 wt %≦C≦2.5 wt % and 3.0 wt %<Si≦5.5 wt %, and a carbon equivalent (the value of CE) defined as “C(wt %)+1/3Si(wt %)” of 2.9 to 3.5. This material is made to be in a half-melted state with 35 to 50 wt % of a solid phase to be cast under a pressure load.

Abstract: A reshaped human anti-HM 1.

Abstract: A thixocast casting material is formed of an Fe—C—Si based alloy in which an angle endothermic section due to the melting of a eutectic crystal exists in a latent heat distribution curve and has a eutectic crystal amount Ec in a range of 10% by weight<Ec<50% by weight. This composition comprises 1.8% by weight≦C≦2.5% by weight of carbon, 1.4% by weight≦Si≦3% by weight if silicon and a balance of Fe including inevitable impurities.

Abstract: An injection mold for semi-solidified Fe alloy includes a scalping gate for eliminating surface oxide film of a semi-solidified Fe alloy injected into the mold cavity from a pressure chamber. The scalping gate is arranged between the pressure clamber and a runner that is in communication with the mold cavity. The mold halves and the scalping gate are each formed of a copper alloy having a thermal conductivity of not less than 120 W/(m·K) and a hardness of not less than 180 HB. The mold halves and the scalping gate each has a cermet layer consisting essentially of at least one member selected from a group consisting of Co, Cu, Cr and Ni. The cermet layer is formed by electro-spark deposition, via an intermediate layer of Ni alloy also formed by electro-spark deposition.

Abstract: The present invention discloses reshaped antibody to human medulloblastoma cells comprising:

Abstract: A method for screening substances that inhibit binding between a TAK1 polypeptide and a TAB1 polypeptide, which comprises contacting the TAB1 polypeptide to the TAK1 polypeptide and a test sample and then detecting or determining the TAK1 polypeptide that is bound to the TAB1 polypeptide.

Abstract: A method for screening substances that inhibit binding between a TAK1 polypeptide and a TAB1 polypeptide, which comprises contacting the TAB1 polypeptide to the TAK1 polypeptide and a test sample and then detecting or determining the TAK1 polypeptide that is bound to the TAB1 polypeptide.

Abstract: The present invention discloses a reshaped human antibody against human IL-8 comprising:

Abstract: A reshaped human antibody is characterized as having the same binding affinity for IL-8 as a chimeric antibody but with low immunogenicity in comparison. The reshaped antibody has the following elements: a human L chain C region or a human L chain FR and an L chain CDR from a mouse monoclonal antibody against human IL-8 and a human H chain C region or a human H chain FR and an H chain CDR of mouse monoclonal antibody against human IL-8. Since the reshaped human antibody has low immunogenicity to humans, it is suitable for use in medical treatment of a variety of medical conditions.

Abstract: A method for the quantitative determination of telomerase activity comprising: amplifying an oligonucleotide sequence synthesized by a DNA synthesis reaction with a telomerase, using a primer modified with either of two materials capable of mutually binding to each other, in the presence of a radioisotope element; allowing the resulting reaction product to bind to a fine particle previously coated with the other of said two materials capable of mutually binding to each other; and measuring scintillation generated from the fine particle due to said binding to quantitatively determine the telomerase activity.

Abstract: The present invention discloses reshaped antibody to human medulloblastoma cells comprising: (A) an L chain comprising: (1) a human L chain C region, and (2) an L chain V region comprising human L chain FRs and L chain CDRs of mouse monoclonal antibody ONS-M21 to human medulloblastoma cells; and, (B) an H chain containing: (1) a human H chain C region, and (2) an H chain V region comprising human H chain FRs and H chain CDRs of mouse monoclonal antibody ONS-M21 to human medulloblastoma cells. Since the majority of this reshaped human antibody is derived from a human antibody and mouse CDRs have a low level of antigenicity, the reshaped human antibody of the present invention has a low level of antigenicity in humans, and is therefore expected to be useful as a therapeutic agent and diagnostic tool for brain tumors such as medulloblastoma which strongly express antigen that is recognized by this antibody.

Abstract: A thixocast casting material is formed of an Fe--C--Si based alloy in which an angle endothermic section due to the melting of a eutectic crystal exists in a latent heat distribution curve and has a eutectic crystal amount Ec in a range of 10% by weight <Ec<50% by weight. This composition comprises 1.8% by weight .ltoreq.C.ltoreq.2.5% by weight of carbon, 1.4% by weight .ltoreq.Si.ltoreq.3% by weight of silicon and a balance of Fe including inevitable impurities.

Abstract: A reshaped antibody comprising:(A) L chains comprising:(1) a human C region, and(2) an L chain V region comprising human L chain FRs and L chain CDRs of a mouse monoclonal antibody; and(B) H chains comprising:(1) a human H chain C region, and(2) an H chain V region comprising human H chain FRs, and H chain CDRs of a mouse monoclonal antibody to human IL-6. Since the major portions of the reshaped human antibody are derived from human, and the mouse CDRs are less immunogenic, then the present reshaped human antibody is less immunogenic, and therefore inhibits information transfer by IL-6, and is promising as a therapeutic agent for diseases caused by IL-6.

Abstract: Monoclonal antibodies immunospecific for the neutrophil chemotactic factor, IL-8, have been humanized by reshaping the variable regions to conform more closely to human counterparts. These antibodies are useful in immunoassays to detect IL-8 and as ligands on immunoaffinity columns for purification of human IL-8. In addition, the humanized antibodies have an antiinflammatory effect in patients.

Abstract: Monoclonal antibodies immunospecific for the neutrophil chemotactic factor, IL-8, have been humanized by reshaping the variable regions to conform more closely to human counterparts. These antibodies are useful in immunoassays to detect IL-8 and as ligands on immunoaffinity columns for purification of human IL-8. In addition, the humanized antibodies have an antiinflammatory effect in patients.

Abstract: Monoclonal antibodies immunospecific for the neutrophil chemotactic factor, IL-8, have been humanized by reshaping the variable regions to conform more closely to human counterparts. These antibodies are useful in immunoassays to detect IL-8 and as ligands on immunoaffinity columns for purification of human IL-8. In addition, the humanized antibodies have an antiinflammatory effect in patients.

Abstract: The present invention discloses a reshaped human antibody against human IL-8 comprising:(A) L chains each comprising:(1) a human L chain C region; and,(2) an L chain V region comprising a human Lchain FR, and an L chain CDR of mouse monoclonal antibody against human IL-8; and,(B) H chains each comprising:(1) a human H chain C region; and,(2) an H chain V region comprising a human Hchain FR, and an H chain CDR of mouse monoclonal antibody against human IL-8. Since the majority of this reshaped human antibody originates in human antibody and the CDR has low antigenicity, the reshaped human antibody of the present invention has low antigenicity to humans, and can therefore be expected to be useful in medical treatment. The present invention further discloses polynucleotides which encode reshaped antibodies against IL-8, as well as host cells and methods to produce these antibodies.

Abstract: A character data input method for an information processing system. Image information on a form which has only a format and on which no data is recorded is read from an input unit for inputting image information. A plurality of input areas in which data is recorded is prescribed by utilizing this image information. Image information on the same form on which data is recorded is thereafter read from the input unit. The format and data are discriminated from image information on the form on which data is recorded based on the recognized character pattern and border pattern of the format and the information prescribing the data input areas to recognize a character pattern in each data input area.

Abstract: A reshaped antibody comprising:(A) L chains comprising:(1) a human C region, and(2) an L chain V region comprising human L chain FRs and L chain CDRs of a mouse monoclonal antibody; and(B) H chains comprising:(1) a human H chain C region, and(2) an H chain V region comprising human H chain FRs, and H chain cDRs of a mouse monoclonal antibody to human IL-6. Since the major portions of the reshaped human antibody are derived from human, and the mouse CDRs are less immunogenic, then the present reshaped human antibody is less immunogenic, and therefore inhibits information transfer by IL-6, and is promising as a therapeutic agent for diseases caused by IL-6.